HC Wainwright & Co. Maintains Buy on LifeMD, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen maintains a Buy rating on LifeMD (NASDAQ:LFMD) and raises the price target from $9 to $10.
November 09, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LifeMD's price target has been raised from $9 to $10 by HC Wainwright & Co. The firm maintains a Buy rating on the stock.
The increase in price target by HC Wainwright & Co. indicates a positive outlook for LifeMD. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100